Genomic Markers for Measuring Metastatic Risk in Breast Cancer Following Primary Treatment

Official Title

Genomic Markers for Measuring Metastatic Risk in Breast Cancer Following Primary Treatment

Summary:

The primary aim of the study is to identify genomic markers as biomarkers of response to chemotherapy among patients with invasive breast cancer. The secondary aim of this study is to use genomic markers to evaluate metastatic risk in breast cancer following primary treatments.

Trial Description

Primary Outcome:

  • Pathologic complete response (pCR)
Secondary Outcome:
  • Time to distant breast cancer recurrence (months)
  • Time to distant metastasis
  • Time to death
The study aims to evaluate genetic markers in breast tumours to predict therapy response and metastatic risk.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society